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Protoporphyrin IX (PpIX), a heme precursor, is a photosensitizer that is selectively accumulated 
in cancer cells when pretreated with its precursor, 5-aminolevulinic acid (5-ALA). Exposure of 
PpIX accumulating-cancer cells to red light induces the generation of reactive oxygen species 
(ROS) and subsequent stimulation of cancer cell death, which is known as 5-ALA-photodynamic 
therapy (5-ALA-PDT). Previously, Dr. Hirasawa's lab discovered that inhibiting the oncogenic 
Ras/MEK pathway increases PpIX accumulation in cancer cells by suppressing PpIX efflux and 
PpIX conversion to heme. Here, we sought to determine whether the increase of PpIX 
accumulation by MEK inhibition promotes 5-ALA-PDT efficacy. First, we classified seven 
human cancer cell lines into three groups – sensitive, moderately sensitive, and least sensitive –
based on their sensitivities to 5-ALA-PDT. Pretreating the moderately sensitive and least 
sensitive cell lines with a MEK inhibitor increased their sensitivities to 5-ALA-PDT, suggesting 
that MEK activity influences PDT sensitivity of cancer cells. MEK inhibition promoted 5-ALA-
PDT induced generation of ROS and the subsequent programmed cell death. Furthermore, 
combined 5-ALA-PDT with a MEK inhibitor was significantly effective in inhibiting the growth 
of tumors in nude mice implanted with human colon cancer cells (DLD-1) and increased their 
overall survival. As the efficacy and safety of MEK inhibitors are clinically established, 





Although the advancements in treatment modalities have improved the outcomes in cancer 
treatment, there is still scope for improvement, and newer and better treatment strategies need to 
be developed to achieve better patient care. Photodynamic therapy is a cancer treatment strategy 
that uses special light-activated chemical compounds called photosensitizers. On exposure to 
light, these photosensitizers generate highly active oxygen moieties that induce cancer cell death. 
Earlier, research at the Hirasawa Lab discovered that targeting a specific cell signaling pathway, 
the Ras/MEK pathway, with inhibitors, could improve the accumulation of photosensitizers in the 
cancer cell. In this study, I sought to determine whether this improved accumulation of 
photosensitizers would improve treatment efficacy. My results show that different cancer cell 
lines have different sensitivities to photodynamic therapy. Further, the Ras/MEK inhibition 
strategy improved the treatment efficacy of photodynamic therapy both in the cells and in mouse 
models of cancer. These are significant preclinical results that show that the Ras/MEK inhibition 





In this thesis, all in vitro experiments were performed by the author, Jayoti Som. The animal 
studies were performed as a group, which included Jayoti Som, Suzette Rutihinda, and Vipin 
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Chapter 1. Introduction 
1.1. Cancer incidence and currently available treatment strategies 
According to the World Health Organization (WHO), cancer is the second leading cause of death, 
and almost 8.8 million people died from cancer in 2015 globally (WHO, Key Facts about Cancer, 
2014). In the United States, 1,735,350 people were diagnosed with cancer in 2018, and $147.3 
billion was spent on cancer care in 2017 (Cancer Statistics Review, 1975-2016 - SEER Statistics, 
2020). The overall rate of cancer mortality is declining globally; as of 2015, the cancer death rate 
decreased by 26% since its peak from the 1990s owing to advanced treatment modalities and 
facilities, early detections, and reduced smoking (Siegel et al., 2018). Surgery, chemotherapy, 
radiotherapy, immune therapy, and combination therapy are the current cancer treatment options. 
The treatment modality is decided based on the cancer type, disease stage and advancement, and 
the age and background of the patient. 
Surgery is the primary therapeutic option for many solid tumors (Klepper, 2016). However, 
surgery has many limitations, such as failure to remove tumors from inoperable areas, inability to 
achieve complete removal of tumors and to distinguish between normal tissue and tumors, and 
damaging healthy tissues leading to decreased quality of life (4). Surgery is also often associated 
with many complications, such as increased risks of infections and prolonged recovery time. 
All the systemic therapies (chemotherapy, immune therapy, hormone therapy, targeted therapy) 
use a single or combination of drugs that target the cancer cells and destroy them locally or 
throughout the body. Drug therapies are often repeated, and every cycle of treatment is usually 




mainly depends on the type and stage of cancer, and age, and overall health of the patient (Atkins 
& He, 2019; Pinedo & Giaccone, 1997) 
Chemotherapy drugs, often referred to as "chemo drugs," target actively growing cells such as 
cancer cells by arresting their cell cycles. The main advantage of chemo drugs is that they 
circulate throughout the patient's body, and hence can be effective for metastasized cancers. 
Traditional chemo drugs could be used before surgery to decrease the size of the tumor, or after 
surgery to prevent cancer recurrences. A combination of multiple chemo drugs often achieves the 
best results (Raguz & Yagüe, 2008). Though traditional chemotherapy drugs are very effective in 
treating cancer, they often cause significant side effects on the body. While attacking highly 
proliferating cancer cells, chemo drugs also damage normal cells with rapid cell division, such as 
hair follicles, the lining of the digestive system, and bone marrow cells, which lead to hair loss, 
gastrointestinal symptoms, and bone marrow degeneration, respectively (Raguz & Yagüe, 2008). 
Resistance to chemo drugs is one of the biggest challenges in cancer treatments. The 
heterogeneous nature of cancer cells and the mutations in the cancer cells contribute to the 
development of resistance to chemo drugs (Gerber, 2008). 
Targeted therapies, a recently developed treatment modality, involve monoclonal antibodies or 
small molecule inhibitors, that can be customized depending on the specific genetic background 
and cancer type of the individual patient (Gerber, 2008). This therapy interferes with specific 
molecular components required for tumor growth and progression and does not affect normal 
cells. Monoclonal antibodies exert anti-cancerous activities by different mechanisms such as 
binding and neutralizing ligands to disrupt tumor growth, blocking receptor binding sites 




immunity (Scott et al., 2012). As of December 2019, 79 therapeutic mAbs have been approved 
by the United States Food and Drug Administration (US FDA) (Lu et al., 2020). 
It has been reported that small molecule inhibitors that interfere with cell signaling pathways, 
such as the tyrosine kinase signaling pathway, are effective for cancer treatment (Gerber, 2008; 
Targeted Cancer Therapies Fact Sheet - National Cancer Institute, 2020). The various tyrosine 
kinase signaling pathways promote cell growth, proliferation, and angiogenesis and are usually 
activated in cancers. Targeting these pathways with small molecule inhibitors is an economical 
and effective strategy for cancer treatment. Further, the small molecule inhibitors could be 
designed to target multiple proteins and signaling pathways, and could hence be more effective 
compared to monoclonal antibodies (Targeted Cancer Therapies Fact Sheet - National Cancer 
Institute, 2020). However, targeted therapy drugs can cause side effects different from those 
induced by chemo drugs, such as diarrhea, liver problems, high blood pressure, skin rashes, and 
blood clotting. These side effects, however, are easily tolerated, and therefore cancer therapies 
with small molecule inhibitors are considered less toxic compared to chemotherapy drugs. 
Nevertheless, it is challenging to find the right dosage of small molecule inhibitors for effective 
treatments (Gerber, 2008; Targeted Cancer Therapies Fact Sheet - National Cancer Institute, 
2020). Additionally, the treatment outcome is highly patient-dependent. 
Radiotherapy uses high energy radiation to damage the DNA of cancer cells extensively, slowing 
down tumor growth or killing tumors (Radiation Therapy for Cancer - National Cancer Institute, 
2020; The American Cancer Society Medical and Editorial Content Team, 2018). Two types of 
radiation therapy are used to treat cancer – external beam and internal beam. The radiation 
therapy with an external beam involves a machine emitting the radiation, specifically on the 




source that is placed within the body. Internal radiation therapy with a liquid radiation source is 
given through an injection, swallowing as a capsule, or IV channel, which travels through the 
bloodstream. While killing cancer cells, radiation can also damage healthy tissues. The side 
effects depend on the area of treatment and include fatigue, exhaustion, diarrhea, hair loss, skin 
problems, and increased risk of developing other cancers (Radiation Therapy for Cancer - 
National Cancer Institute, 2020; The American Cancer Society Medical and Editorial Content 
Team, 2018). 
Immunotherapy activates the patient's immune system to fight against tumors. Different types of 
immunotherapies are currently used to treat cancer, including monoclonal antibodies that 
specifically target cancer cells, immune checkpoint inhibitors that increase recognition of cancer 
cells by the immune system, cancer vaccines that boost cancer immunity, and adoptive cell 
transfers that activate antitumor cytotoxic T cells (American Cancer Society, 2015; National 
Cancer Institute, 2019). The dosage and duration of immunotherapy depend on the type and stage 
of cancer. Although immunotherapy is not as common as surgery or chemotherapy, it has been 
approved for the treatment of many cancers. The common side effects of immunotherapy are 
pain, rash, itching, swelling, redness, diarrhea, blood pressure changes, trouble breathing, and 
heart palpitations (American Cancer Society, 2015). 
Although chemotherapy and radiotherapy are widely used in clinics, surgery remains the primary 
treatment for solid tumors. As surgery without substantial damage to the healthy tissues is very 






1.2. Photodynamic Therapy (PDT) 
PDT is an FDA approved, drug-device combination for cancer treatment. It involves the use of 
photosensitizers (PS), which are chemical compounds that are activated when exposed to light. 
The activated photosensitizer stimulates the conversion of molecular oxygen present in the 
tissues to highly toxic molecules called reactive oxygen species (ROS). (Agostinis et al., 2011) 
(Fig 1). None of the three components of PDT, PS, light, or molecular oxygen are toxic by 
themselves, but when they are combined, they generate photo-toxicity and induce cancer cell 
death. PDT has been approved for the treatment of colon cancer, head and neck cancer, prostate 
cancer, esophageal cancer, melanoma, actinic keratosis, and non-small cell lung carcinoma 
(Huang, 2005; Wan & Lin, 2014). 
PDT is a two-step process – administration of PS and irradiation of the tumor site with visible 
light. Owing to the increased metabolic rate and decreased lymphatic drainage in the tumor, the 
PSs accumulate in the cancer cells (Briel-Pump et al., 2018; Kim et al., 2011). On exposure to 
specific wavelengths of light, PSs are activated, inducing the generation of toxic ROS, which 
oxidizes biomolecules in the cancer cells resulting in cell death. Since the accumulation of the PS 
is limited to the cancer cells and the tumor tissue, and only the tumor is exposed to light during 
the treatment, the toxic effects are limited to the tumor, and the surrounding cells are spared. In 
addition to the direct killing of cancer cells, PDT damages tumor vasculature and initiates 
inflammatory responses leading to tumor regression (Agostinis et al., 2011). Unlike surgery, 
chemotherapy, and radiotherapy, PDT is less expensive and less invasive and requires short 





However, similar to other cancer treatments, PDT also has some limitations. Failure to 
accumulate a sufficient amount of the PS in the tumor could result in a partial or incomplete 
treatment outcome. Hyper-photosensitivity is another challenge for many patients, which can 
cause skin burns, rashes, and pain. Most importantly, the treatment efficacy is dependent on the 
adequate illumination of the tumor. Since the penetration potential of light is limited to about 1 
cm into the human tissue, sufficient illumination of large, deep, and metastasized tumors is often 




Fig 1: The three components of photodynamic therapy (PDT). PDT involves the use of a 
photosensitizer (PS), which gets accumulated in cancer cells. On irradiation with light of specific 
wavelengths, the photosensitizer induces the generation of reactive oxygen species, which elicit 



























1.3. The three components for PDT 
1.3.1. Photosensitizers (PS) 
PSs are molecules that can be activated by light. Many PSs possess a tetrapyrrole structure 
similar to heme in hemoglobin and usually have an absorption maximum between 600 nm and 
800 nm (Castano et al., 2004a). An ideal PS should not show any dark toxicity; that is, they 
should not be toxic in the absence of light, and should be rapidly cleared from the body 
(Agostinis et al., 2011). Light exposure activates the PSs and induces the generation of singlet 
oxygen (1O2) or superoxide (O2
-), which, in turn, induce cancer cell death (Huang, 2005). 
Many of the current approved PSs belongs to the porphyrin family (Table 1). Photofrin is the first 
FDA approved PS for cancer treatment (Huang, 2005). 5-Aminolevulinic Acid (5-ALA), the 
precursor of protoporphyrin IX (PpIX), is one of the widely used PSs in PDT. PSs can be given 
directly for tumor cell accumulation. However, some PSs are administered as a prodrug, which is 
then metabolically converted to the active PS, to avoid intrinsic PS sensitivity (Sansaloni-Pastor 
et al., 2019). 5-ALA is a prodrug, which does not have any fluorescence property. Once 
administered, it gets metabolically converted to the active PS, protoporphyrin IX ( PpIX), 
through the heme biosynthesis pathway. European Medicine Evaluation Agency (EMEA) 
approved ALA esters and derivatives for papillary bladder cancer (Casas et al., 2009; Krammer 


































































Fig 2: Schematic diagram of PDT on cancer cells and normal cells. The photosensitizers get 
selectively accumulated in cancer cells. On exposure to light of specific wavelengths, the PSs get 
activated and induce the generation of ROS, leading to cell death. However, the PSs do not 















1.3.2. Light and light sources 
The activation of the PS is dependent on adequate light exposure. Most PSs can be activated by 
light in the visible spectrum (400 – 600 nm). Although lower wavelength lights have higher 
energy and can efficiently activate the PSs, they lack sufficient tissue-penetration potential. Red 
light (~600 nm) has the highest penetration ability, whereas blue light (~400 nm) has the least. 
Light sources up to a wavelength of 800 nm (far red) have enough energy to generate singlet 
oxygen (1O2) in cells accumulated with PSs. Therefore, most PDT applications prefer light in the 
range of 600 – 800 nm for attaining maximum tissue-penetration. 
The light source is chosen based on the size, grade, type, and location of the tumor, and the type 
of PS. Noncoherent light sources (regular arc lamps) were the first light sources used in PDT. 
They were affordable, safe, and easy to use. However, they had many disadvantages, such as lack 
of energy control, high thermal effects on the subject, and significantly low light intensities. 
Therefore, lasers are currently used as light sources in PDT. These light sources can deliver light 




The third element of PDT is molecular oxygen. Sufficient oxygen is required for the effective 
generation of ROS, which subsequently oxidizes the cells and kills them. It has been shown that 





While the unstimulated PSs exist in the ground state (0PS), they are rapidly activated to an 
excited state (1PS) when exposed to light of sufficient energy. Fig 3 is adapted from the 
Jablonski Diagram, which shows the fate of the excited PS. From the excited state, PSs can take 
two different pathways to return to the ground state (Fig 3). First, they can release energy by 
emitting heat and fluorescence. Alternatively, they move to a triplet state (3PS) by intersystem 
crossing. As it returns to the ground state, it releases energy, which is transferred to oxygen to 
generate reactive oxygen species (ROS), such as singlet oxygen and free radicals. These ROS 
mediate cellular toxicity. The activated sensitizer can undergo two kinds of reactions. First, it can 
react directly either with the substrate, such as the cell membrane or a molecule, transferring a 
hydrogen atom to form radicals. The radicals interact with oxygen to produce oxygenated 
products (type I reaction). Alternatively, the activated sensitizer can transfer its energy directly to 
oxygen, to form singlet oxygen — a highly reactive oxygen species. These species oxidize 
various substrates (type II reaction). The ROS thus generated oxidizes cellular components 




Fig 3: Jablonski Diagram: A schematic representation of PSs activation and generation of 
reactive oxygen species. The PS in its ground state (S0) is readily excited by light to an excited 
state (S1). From the excited state, the PS returns to the ground state by releasing energy in the 
form of heat or light (fluorescence) or undergoes intersystem crossing to attain a triplet state (T1). 
The PS in the triplet state then releases electrons either to molecular oxygen (type I reaction) or to 
other biomolecules (type II reaction) to generate highly toxic reactive oxygen species (ROS) that 
















1.4. Protoporphyrin IX (PpIX) 
5-ALA is a precursor of heme in the heme biosynthesis pathway (Ishizuka et al., 2011). It is 
metabolically converted to protoporphyrin IX (PpIX) through several enzymatic processes (Fig 
4). The PpIX produced in the cells can either be converted to heme by the enzyme ferrochelatase, 
or effluxed out of the cell into extracellular space through the ATP-binding cassette (ABC) 
transporters such as ABCB1, ABCG2, or ABCB6. The heme biosynthesis pathway in a normal 
cell is highly regulated. The synthesis of 5-ALA and the conversion of PpIX to heme are rate-
limiting steps in the pathway. In addition, the rate of ALA synthesis is regulated by the heme 
concentration in the cell. Higher amounts of heme act as a suppressor of ALA synthesis. 
However, in a cancer cell, the pathway is dysregulated, and several steps in between ALA 
synthesis and the generation of PpIX are overactivated. However, the final enzyme in the 
pathway, FECH, is downregulated in several cancers. Administration of exogenous 5-ALA by-
passes the negative regulation on ALA synthesis and results in increased flux through the 
pathway. However, due to the downregulation of FECH, the synthesized PpIX is not efficiently 
converted to heme, resulting in PpIX accumulation in the cancer cells (Ishizuka et al., 2011). 
PpIX is a photoactive compound and can be excited by visible light. Exposure to red or blue light 
activates PpIX, inducing the generation of ROS, which oxidizes different biomolecules in cancer 
cells resulting in cell death. Under blue light, PpIX emits red fluorescence that can be used for 




Fig 4: The heme biosynthesis pathway and the use of 5-ALA for photo-diagnosis and 
photodynamic therapy of cancer. 5-ALA is synthesized in the mitochondria by the enzyme 
ALA synthase by combining one molecule of glycine with one molecule of succinyl CoA. Once 
synthesized, 5-ALA is transported across the mitochondrial membrane into the cytoplasm, where 
the enzymes of the heme biosynthesis pathway convert it into coproporphyrinogen III. 
Coproporphyrinogen III is transported back into the mitochondria, where it gets converted to 
protoporphyrin and then into protoporphyrin IX (PpIX). Enzyme ferrochelatase (FECH) chelates 
a ferrous ion to PpIX and converting it into heme. Heme is then transported into the cytoplasm, 
where it is either used or broken down. The synthesis of 5-ALA (ALA synthase-catalyzed) and 
the conversion of PpIX to heme (FECH-catalyzed) are rate-limiting steps in the pathway. Further, 
there is a feedback inhibition loop between heme and the activity of ALA synthase. However, in 
a cancer cell, when exogenous 5-ALA is administered, the feedback inhibition on ALA synthase 
is overridden. PpIX gets accumulated owing to the higher activity of the heme biosynthesis 
enzymes and the reduced activity of FECH in cancer cells. This PpIX emits red fluorescence, 
when irradiated with blue light, and can be used to distinguish cancer cells from surrounding 
normal cells (photodynamic diagnosis; PDD). Additionally, irradiating PpIX with blue or red 
light, induces the generation of reactive oxygen species (ROS), which oxidizes cellular 











1.5. The Ras/MEK signaling pathway and PpIX accumulation 
Ras is a member of a family of proteins that belong to a class of proteins called small GTPases 
and are involved in transmitting signals within the cells. Ras proteins function as binary 
molecular switches and control intracellular signaling networks. The Ras-regulated signal 
pathways control processes such as actin cytoskeletal integrity, cell proliferation, cell 
differentiation, cell adhesion, apoptosis, and cell migration. Ras and Ras-related proteins are 
often deregulated in cancers, leading to increased invasion and metastasis, and decreased 
apoptosis (Khan et al., 2019; Shields et al., 2000). 
The RAS family of proteins were initially identified as Rat Sarcoma factors and is the first 
oncogene that was identified. The Ras superfamily consists of several members, including Ras, 
Rab, Rho, Arf, and Ran sub-families. The RAS proteins are monomeric 21-kDa proteins that 
have a high degree of homology. These proteins function as GTP/GDP-binding signal-
transducing molecules from the cell surface to the nucleus. 
Ras activates several pathways, of which the mitogen-activated protein kinase (MAPK) cascade 
has been well-studied (Carriere et al., 2008; Friday & Adjei, 2008; Schubbert et al., 2007; 
Weidhaas et al., 2006). This cascade transmits signals downstream and results in the transcription 
of genes involved in cell growth and division. Other Ras-activated signaling pathways are p38 
mitogen-activated protein kinase kinase (P38 MAPK) and Phosphoinositide 3-kinase (PI3K) 
signaling pathways (Yoshioka et al., 2018). 
MAPK signaling is crucial for maintaining normal physiological processes, including 
proliferation and differentiation. The MAPK signaling is complex and involves a large number of 
intermediate molecules, of which the RAS signaling pathway is an important component. The 




signal kinases, mitogen extracellular kinase (MEKO, and extracellular signal-related kinase 
(ERK). 
The Ras superfamily members Ras, Rac, Rho, and Cdc42 are involved in the remodeling of the 
cortical actin cytoskeleton following growth factor stimulation. Ras-GAP, a major regulator of 
Ras, contains structural domains called the SH3 domains, that are involved in Rho activation and 
subsequent actin remodeling (Leblanc et al., 1998). 
The Ras signaling pathways are important regulators of cell proliferation, senescence, and 
apoptosis. Several Ras downstream effectors have dual roles in each of these processes, such that, 
under one set of conditions, they promote cell cycle progression and proliferation, while in a 
different paradigm, they drive cell cycle arrest and apoptosis (Stout et al., 2014; Xiang et al., 
2017). Besides, there are cross talk channels between the Ras downstream effectors that underlies 
the molecular basis of the intricate control mechanisms that govern cell growth and cell death 
(Chow et al., 2017). 
The normal function of the MAPK signaling pathway is to maintain cellular homeostasis. 
Mutations in the pathway elements lead to signal imbalance and can potentially result in cancer. 
The Ras/MEK pathway is constitutively activated in many cancers (Datta et al., 2017; Santarpia 
et al., 2012; Schubbert et al., 2007). Ras activates several downstream cascade branches, 
including the RAF/MEK/ERK, PI3K/AKT, and RalGDS/Ral signal molecules critical for cancer 
progression. It has been reported that the interplay between oncogenic Ras and p53, the master 
tumor suppressor, plays critical roles in the progression of cancer, cellular autophagy, and 
epithelial-mesenchymal transition (EMT) (X. Zhang et al., 2017). Further, this interplay is also 
reported to regulate the development of chemotherapy resistance and metastasis in several 




effectors, including MAPK and MEK, are considered therapeutic targets for several cancers 
(Chow et al., 2017; Janda et al., 2002; Liang et al., 2019; Stout et al., 2014; X. Zhang et al., 
2017). 
Several previous studies have shown that the activation of oncogenic pathways, including the Ras 
signaling pathway, increases 5-ALA-induced PpIX accumulation (Juzeniene et al., 2007; Li et 
al., 1999; X. Yang et al., 2016). Therefore, it was speculated that Ras/MEK activation would 
increase PpIX accumulation in cancer cells by enhancing the metabolic activities of the heme 
biosynthesis pathway. However, previous studies at the Hirasawa Lab discovered an opposite 
effect (Chelakkot et al., 2019; Yoshioka et al., 2018). They showed that the inhibition of one of 
the Ras downstream elements, MEK, significantly increases 5-ALA-induced PpIX accumulation 
in tumors (Yoshioka et al., 2018). Further, they demonstrated that MEK inhibition downregulated 
the expression of ABCB1, a member of ABC transporter, and thus decreased PpIX efflux out of 
the cells. Additionally, MEK inhibition reduced the activity of FECH, resulting in the low 
conversion of PpIX to heme (Yoshioka et al., 2018). These two independent phenomena together 
contributed to the enhanced accumulation of PpIX in cancer cells treated with a MEK inhibitor. 
They concluded that the oncogenic Ras/MEK pathway has a negative effect on 5-ALA-induced 
PpIX accumulation in cancer cells. 
 
1.6. MEK inhibitors in cancer treatment 
MEK1 and MEK2 are key elements in the Ras/MEK pathway and play important roles in 
regulating angiogenesis, cell proliferation, and cell death. In clinics, MEK inhibitors are widely 




(Sanlorenzo et al., 2014). PD98059 is one of the first MEK inhibitors, which inhibits 
phosphorylation of downstream elements in the Ras/MEK pathway. U0126 inhibits cell 
proliferation, survival and increases cell death by apoptosis (Hawkins et al., 2008). Moreover, 
U0126 inhibits inflammatory responses by suppressing cytokine production (Yoshioka et al., 
2018). 
Trametinib is the first MEK inhibitor approved by the FDA for the treatment of melanoma 
(Alexander M Menzies & Long, 2014). In a randomized control trial, Trametinib showed 
significantly improved treatment outcome and progression-free survival of patients compared to 
chemotherapy (Alexander M Menzies & Long, 2014). Trametinib is also used with dabrafenib, a 
BRAF inhibitor in clinics, as a combination for treating metastasized non-small cell lung cancer 
(NSCLC) (Robert et al., 2019). Mutations in the BRAF oncogene are found in several cancers. 
The most common activating mutation in the BRAF oncogene is a valine substitution for 
glutamate at residue 600 (V600E) within the BRAF kinase. Although BRAF-targeted therapies 
are effective in many cancers, inhibiting BRAF activated the downstream MEK, resulting in the 
development of treatment resistance and disease relapse. 
On the other hand, targeting both BRAF and MEK improved the response rate and the treatment 
outcome (Khunger et al., 2018; Robert et al., 2019). MEK inhibitor cobimetinib was approved by 
FDA in 2015 with BRAF inhibitor vemurafenib as a combination drug for the treatment of 
inoperable or BRAF V600E, or V600K mutated advanced melanoma. Preclinical studies with 
cobimetinib have demonstrated its ability to inhibit cell division and tumor growth (Cheng et al., 
2017; Research, 2018). In June 2018, the US FDA and European Medicines Agency (EMA) 
approved MEK inhibitor Binimetinib with BRAF inhibitor dabrafenib for the treatment of 




PubChem Compound Database, 2018). Binimetinib is a highly selective MEK inhibitor and has 
the potential to treat many metastasized cancers. 
Patients treated with MEK inhibitors sometimes develop mild side effects such as rashes, 
peripheral edema, diarrhea, and fatigue (Welsh & Corrie, 2015). The MEK inhibitor used in the 
current study is selumetinib, which is highly selective to inhibit MEK1 and MEK2 (Wu & Park, 
2015). Selumetinib has been evaluated in multiple Phase I/II clinical trials. Studies have shown 
that selumetinib has moderate anti-cancer effects for low-grade gliomas and other cancers, hence 
not very effective as monotherapy (O'Neil et al., 2011). Selumetinib, combined with other 
chemotherapy such as docetaxel, PI3K inhibitors, carboplatin, and temsirolimus, might be very 











































Chapter 2. Hypothesis and Study Objectives 
2.1 Hypothesis 
Based on the previous results from the Hirasawa Lab (Yoshioka et al., 2018), which showed that 
MEK inhibition increases 5-ALA-induced PpIX accumulation, I sought to determine whether 
increased PpIX accumulation with MEK inhibitor could enhance the sensitivity of cancer cells to 
5-ALA-PDT. I hypothesized that the increased PpIX in the cancer cells would induce the 
generation of higher amounts of ROS and would trigger more extensive cell death. I also 
hypothesized that combining MEK inhibition with PDT would enhance the efficacy of the 
treatment. 
 
2.2 Study objectives 
To determine the effect of MEK inhibition on the efficacy of 5-ALA-PDT, first, I sought to 
evaluate the sensitivities of various cancer cell lines to 5-ALA-PDT. Next, the effect of MEK 
inhibition on 5-ALA-PDT efficacy was determined in the cell lines. Further, animal models of 




Chapter 3. Materials and Methods 
3.1. Cell culture 
A panel of cancer cell lines, including colon cancer (DLD-1), lung cancer (H460 & H1299), 
breast cancer (Hs 578T & MDA-MB-231), and glioma (U118 & U251) were used in the study. 
Lung cancer (H460 & H1299) cell lines were purchased from American Type Culture Collection 
(ATCC). Glioma cells (U118 & U251) were obtained from Dr. Tommy Alain (University of 
Ottawa). The cell lines were authenticated by Short Tandem Repeat (STR) DNA analysis (TCAG 
Sick kids, Toronto and DDC Medical, USA). 
All cell lines were maintained in high glucose Dulbecco's modified Eagle's medium (DMEM) 
(Invitrogen, Canada). DMEM was supplemented with 10% fetal bovine serum (FBS) (Invitrogen, 
Canada), sodium pyruvate (Thermo Fisher Scientific, Canada), and antibiotic-antimycotic 
mixture (Invitrogen Canada) (100 Units/ml penicillin G sodium). The cells were maintained at 37 
°C in a humidified atmosphere with 5% CO2. 
 
3.2 In vitro drug treatments 
3.2.1. Treatment with MEK inhibitor, U0126 
MEK inhibitor U0126 was obtained from Cell Signaling Technology (CST) (Danvers, MA). Five 
grams of U0126 was dissolved in 500 µl of dimethyl sulfoxide (DMSO) (Sigma, France) to make 
a 25.97 mM stock solution. The stock solution was stored at -80 °C. Cells were treated with 





3.2.2. Treatment with 5-aminolevulinic acid (5-ALA) in vitro 
5-ALA was obtained from Sigma (Oakville, ON). One gram of 5-ALA was dissolved in 50 ml of 
DMEM to make a 120 mM stock solution. The stock solution was stored at -20 °C. At 24 h after 
plating or 20 h after U0126/DMSO treatment, cells were treated with 5-ALA (0.2 mM, 1 mM, 5 
mM) and then incubated for 4 h in the dark. 
 
3.3. In vivo drug treatments 
3.3.1. Administration of MEK inhibitor selumetinib 
MEK inhibitor, Selumetinib (Selleckchem, Houston, TX), was dissolved in 0.5% polymethyl 
cellulose (Sigma, USA). A volume of 250 l of control vehicle or selumetinib (150 mg/kg of 
mouse body weight) was administered to each mouse by oral gavage at 6 h prior to 5-ALA 
injection. 
3.3.2. Administration of 5-ALA in vivo 
Athymic nude mice were injected intraperitoneally (i.p) with 5-ALA (200 mg/ kg BW) in sterile 
saline (0.85% NaCl) (Hospira, Canada) and kept in the dark for 2 h before light irradiation. 
 
3.4. In vitro protoporphyrin IX (PpIX) measurements 
The cells (5 ×104/well in 500 µl DMEM) were plated in a 24-well plate and incubated for 24 h to 
attain cell confluency of 75% - 80%. The medium was replaced with media containing U0126 or 
DMSO and then incubated for 20 h. After the incubation, they were treated with different 




radioimmunoprecipitation assay (RIPA) buffer (PBS pH 7.4, NP-40 1% (Sigma, USA), 0.1% 
sodium dodecyl sulfate (SDS) (Bio-Rad, Canada), 0.5% sodium deoxycholate (Sigma, USA). 
Cell lysates were diluted in PBS (190 l of PBS and 5 l cell lysate), and PpIX fluorescence was 
measured using Biotek Synergy MX fluorescent plate reader with a 405 nm excitation and 635 
nm emission filter. 
 
3.5. In vitro photodynamic therapy (PDT) 
The cells (5 ×103 /well in 100 l DMEM) were plated in a 96-well plate and incubated for 24 h to 
attain cell confluency of 75% - 80%. The medium was replaced with media supplemented with 
U0126 or DMSO and then incubated for 20 h. After the incubation, they were treated with 
different concentrations of 5-ALA (0.2 mM, 1 mM, or 2 mM) for 4 h in the dark. The culture 
medium was replaced with fresh medium, and the plates were irradiated with a 625 nm laser for 3 
mins using a Theralase Modular Light source (TLC-3000A, Canada) (light density of 150 
mW/cm2 for 3 min, total energy of 27 J/cm2). 
 
3.6. Measurement of cell viability 
At 24 h after PDT, a colorimetric cell viability kit (CCVK) (PromoCell, Canada) was used to 
measure cell viability. A volume of 10 l of the reagent was added to each well (100 l). They 
were incubated for 45 mins in the dark, and the absorbance was measured at 450 nm using a plate 
reader (Biotek, Vermont, USA). This assay uses tetrazolium salt WST-8, which is reduced by 
cellular dehydrogenase and formed an orange formazan product. The amount of this finished 




3.7. Animal studies 
3.7.1. Mouse strains and housing 
Eight-week-old athymic nude mice were obtained from Charles River Laboratories (strain 490, 
Homozygous, Crl:NU(NCr)-Foxn1nu), (Montreal) and housed in isolated ventilated caging units 
within the pathogen-free barrier at the central animal care facility in the Health Sciences Center at 
Memorial University of Newfoundland. The animal care protocols were approved by the 
Institutional Animal Care Committee in accordance with the Canadian Council on Animal Care 
guidelines. Mice were fed with Laboratory Rodent Diet 5010 food (27.5 % protein, 13.5 % fat, 
59 % carbohydrate) (OM Nutrition International, Richmond, IN) with sterile water ad libitum and 
were housed under a 12-hour light/dark cycle. 
3.7.2. Tumor xenograft mouse model 
Human colon cancer cells (DLD-1) were grown as a monolayer in a 10 cm culture dish. Cells 
were trypsinized and washed three times in PBS. 2 ×106 cells in 100 l PBS were injected 
subcutaneously into the right hind flank of the athymic nude mice. 
3.7.3. PDT with MEK inhibitor, selumetinib 
A schematic of the animal experiment is shown in Fig 5. After the development of palpable 
tumors (4-5 mm in diameter), selumetinib (150 mg selumetinib/kg BW) or control vehicle was 
administered to the mice by oral gavage. At 6 h after selumetinib treatment, the mice received 5- 
ALA (200 mg/kg BW) by i.p injection. All animals were anesthetized during the light treatment 
using isoflurane. A laser (Omicron Laserage, Germany) with the frontal light distributor 




J/cm2). Animals were kept in their home cages and maintained in a dark environment for 24 h 
after the light treatment to avoid 5-ALA-induced photosensitivity. 
3.7.4. Measurement of tumor size 
Tumor sizes were recorded in two dimensions using a pair of calipers every day till the tumor 





Fig 5: In vivo experimental design. Athymic nude mice bearing human colon DLD-1 tumors on 
the right flank were treated p.o. with Selumetinib (250 mg/kg) for 6 h and then i.p. with 5-ALA 
(200 mg/kg) for 2 h. The tumors were irradiated with a 635 nm laser for 5 minutes to deliver an 
energy of 40 J/cm2. The tumor sizes and mouse survival were monitored every day. Mice with 
tumor size of 15 mm in diameter in any directions were sacrificed as they were considered to 















3.8. Statistical analysis 
One-way ANOVA with Tukey's post-hoc test or Student's t-test was performed using GraphPad 
Prism 4.0 (GraphPad Software, La Jolla, CA, USA) to analyze the data. p<0.01 was considered 
significant for in vitro experiments and p<0.05 for in vivo experiments. Mouse survival was 




Chapter 4. Results 
4.1. Sensitivity of different cancer cell lines to 5-ALA-PDT 
To determine the sensitivity of different cancer cell lines to 5-ALA-PDT, we used seven cancer 
cell lines (U251, U118, DLD-1, H1299, Hs 578T, MDA-MB-231, and H460). The cells were 
plated in a 96-well plate, and, 24 h later, treated with different concentrations of 5-ALA (0.2 mM, 
1 mM, or 5 mM) for 4 h in the dark and then irradiated at 625 nm red laser for 3 min using a 
Theralase Modular Light source (TLC-3000A, Canada). Cell viability was measured at 24 h after 
5-ALA-PDT using a colorimetric cell viability kit (PromoCell, Canada). A cell line was deemed 
sensitive or not sensitive to the treatment based on the 24 h post-treatment-cell viability. A 
decrease in cell viability was perceived as a direct effect of the treatment, and the cell line was 
considered sensitive to the treatment. Different cell lines showed different levels of sensitivities 
to 5-ALA-PDT (Fig 5). Based on their sensitivity to 5-ALA-PDT, the seven human cancer cell 
lines were classified into three groups – sensitive, moderately sensitive, and least sensitive. U118 
and U251 were killed by 5-ALA-PDT at all the concentrations tested and were classified as 
sensitive cell lines. DLD-1, H1299, Hs 578T, and MDA-MB-231 were sensitive to 5-ALA-PDT 
at the higher concentrations of 5-ALA (1 and 5 mM), but not at the lowest concentration of 5-
ALA (0.2 mM), so they were classified as moderately sensitive cell lines. H460 was resistant to 




Fig 6. Different cell lines have different sensitivities to 5-ALA-PDT. Human glioma (U-118, 
U-251), colon cancer (DLD-1), breast cancer (Hs 578T, MDA-MB-231), and lung cancer (H-
1299, H460) cell lines were treated with 0, 0.2, 1, or 5 mM 5-ALA for 4 h in the dark before PDT 
irradiation with 635 nm light for 100 sec (27 J/cm2). At 20 h after 5-ALA-PDT, cell viability was 
determined using a colorimetric cell viability kit. Data are expressed as the mean ± SD of fold 
changes in cell viability from 3 independent experiments compared to the control untreated cells. 












4.2. MEK inhibition increased PpIX accumulation in moderately sensitive cell lines 
Previously our laboratory demonstrated that MEK inhibition increases PpIX accumulation by 
inhibiting PpIX efflux and conversion to heme (Yoshioka et al., 2018). As sufficient PpIX 
accumulation is essential for effective 5-ALA-PDT, I hypothesized that MEK activation 
underlies the different sensitivities of human cancer cells to 5-ALA-PDT. To test this, I sought to 
determine whether MEK inhibition increases PpIX accumulation and 5-ALA-PDT efficacy in the 
moderately and least sensitive cell lines (Fig 6). Moderately sensitive cells (DLD-1 and Hs 578T) 
were treated with MEK inhibitor, U0126 (20 M), or DMSO (vehicle control), for 20 h and then 
with different concentrations of 5-ALA (0.2, 1 or 5 mM) for 4 h in the dark. The cells were 
washed once with PBS and then lysed with 100 l radioimmunoprecipitation assay (RIPA) 
buffer. PpIX fluorescence in the cell lysates was measured using a Biotek Synergy MX 
fluorescence plate reader with a 405 nm excitation and 635 nm emission filter. Both moderately 
sensitive cell lines showed significantly increased accumulation of PpIX. While DLD1 cells 
showed an increase in PpIX accumulation only when treated with 1 mM 5-ALA, Hs 578T cells 
showed significantly increased PpIX accumulation at both 1 mM and 5 mM 5-ALA, when 




Fig 7. MEK inhibition enhanced 5-ALA-induced PpIX accumulation. Human (A) colon 
cancer cells (DLD-1), and (B) breast cancer cells (Hs 578T) were treated with DMSO or MEK 
inhibitor (U0126) for 20 h, and then with 0.2, 1, or 5 mM 5-ALA and incubated in the dark for 4 
h. The cells were lysed with RIPA buffer, and PpIX fluorescence in the lysates was measured 
using Biotek Synergy MX fluorescence plate reader with a 405 nm excitation and 635 nm 
emission filter. Data are expressed as the mean ± SD of fold changes in PpIX fluorescence from 3 
independent experiments compared to the DMSO treated control. Statistical analysis was carried 












4.3. MEK inhibitor increased sensitivity to 5-ALA-PDT in moderately sensitive cell lines 
Next, I determined whether the increased accumulation of PpIX by MEK inhibition would 
improve the efficacy of 5-ALA-PDT in the moderately sensitive cell lines. DLD-1 and Hs 578T 
were treated with U0126 (20 M) or DMSO for 20 h and then with different concentrations of 5-
ALA (0.2 mM, 1 mM, or 5 mM) for 4 h. PDT was conducted by irradiating cells with a 625 nm 
red laser for 3 min using a Theralase Modular Light source (TLC-3000A, Canada). The efficacy 
of 5-ALA-PDT was determined by a colorimetric cell viability assay (PromoCell, Canada) at  
24 h after treatment. Combined 5-ALA-PDT with U0126 showed significantly higher anti-cancer 
efficacies than 5-ALA-PDT only at the 5-ALA concentration of 1 and 5 mM in both DLD-1 and 
Hs 578T cells. Although combined treatment with U0126 and low ALA concentrations  
(0.2 – 1 mM) did not affect the sensitivity of the least sensitive cell line, H460, a slight but 
significant decrease in cell viability was observed at higher ALA concentrations (5, 7.5, and  
10 mM). These results suggest that MEK activation in cancer cells reduces 5-ALA-mediated 




Fig 8. MEK inhibition increases sensitivity to 5-ALA-PDT. Human (a) colon (DLD-1), (b) 
breast (Hs 578T), and (c) lung (H460) cancer cells were treated with DMSO or the MEK 
inhibitor (U0126) (20 µM) for 20 h, and then different concentrations of 5-ALA in the dark for  
4 h. The cells were then subjected to PDT (635 nm light for 100 seconds: 27 J/cm2). At 20 h after 
treatment, cell viability was assayed using a colorimetric cell viability kit. Data are expressed as 
the mean ± SD fold change in cell viability compared to the control untreated cells from 3 
independent experiments. Statistical analysis was carried out using two-way ANOVA, with 












4.4. Combined 5-ALA-PDT treatment with MEK inhibitor reduced tumor volume and 
increased survival in athymic nude mice 
To broaden our investigation, we next sought to determine whether MEK inhibition could 
promote the efficacy of 5-ALA-PDT in vivo. To answer this, I tested the efficacy of combined 5-
ALA-PDT with the MEK inhibitor in nude mice bearing human tumor xenografts (Fig 8). For the 
in vivo experiments, I used the MEK inhibitor, selumetinib, which is being evaluated in Phase I 
and Phase II clinical trials for colorectal cancer, myeloma, biliary cancer, and hepatocellular 
carcinoma. (Bekaii-Saab et al., 2011; Muchir et al., 2012). Human colon DLD-1 cells were 
injected at the right hind flank of nude mice (2 ×106 cells in 100 l PBS per mouse). When mice 
developed a palpable tumor (3-5 mm in diameter), they were grouped randomly into four groups 
– Control, selumetinib only, 5-ALA-PDT only, and combined 5-ALA-PDT with Selumetinib. 
Each group had nine mice. Selumetinib was administered orally (250 mg/kg BW), while vehicle 
control and 5-ALA-PDT only groups received vehicle (0.5% Propyl Methylcellulose in DW). 
The 5-ALA-PDT only and combined 5-ALA-PDT with Selumetinib groups were 
intraperitoneally injected with 5-ALA (200 mg/kg BW) at 6 h after inhibitor/vehicle treatment, 
followed by PDT at 2 h post-ALA administration. For PDT, a diode laser (Omicron Laserage, 
Germany) and a frontal light diffuser (MedLight, S.A, Switzerland) was used as the light source 
to deliver an energy density of 40 J/cm2. The size of tumors was measured in two dimensions 
every day using a pair of calipers until 60 days after treatment or until the tumor size reached 15 
mm in any dimension. 
As tumors in the control group reached the maximum size within 12 days, all the mice were 
sacrificed (Fig 9). Selumetinib group showed slower but not significantly different tumor growth 




mouse in the selumetinib only group developed unrelated rashes, which was sacrificed before the 
tumor size reached the maximum level. While tumor growth of mice treated with 5-ALA-PDT 
was significantly slower compared to that of mice in the control group, all the mice were 
sacrificed within 23 days after treatment. Combined 5-ALA-PDT with Selumetinib significantly 
improved mice survival compared to control, selumetinib, or 5-ALA-PDT treatment. More 
importantly, four out of nine mice survived until the endpoint of the experiment (60 days after the 
treatment). Three of those mice were tumor-free, and the other had a very small tumor. In mice 
treated with the combined 5-ALA-PDT with Selumetinib, two mice were sacrificed before the 
tumors reached the maximum size due to the development of unrelated rashes. 
These results demonstrate that MEK inhibitors can enhance the efficacy of in vivo ALA-PDT and 
prolong mice survival, suggesting that the combined treatment can be advantageous for cancer 




Fig 9. MEK inhibition enhanced 5-ALA-PDT efficacy in vivo. a) Growth of human colon 
DLD-1 tumors of mice treated with vehicle control (Control), Selumetinib (Selu), 5-ALA-PDT 
(ALA-PDT), or Selumetinib and 5-ALA-PDT (Selu-ALA-PDT). Each group had 9 mice, and 
each line represents the tumor sizes of an individual mouse. b) Kaplan-Meier survival curve 
























Chapter 5. Discussion 
5.1. General discussion 
Photodynamic Therapy (PDT), an alternative cancer therapy system, includes the administration 
of a PS and the production of reactive oxygen species triggered by light exposure, which leads to 
cancer cell death. The reactive oxygen species triggers rapid oxidization of biomolecules and 
cellular components, triggering several death triggers (Castano et al., 2004b, 2005a, 2005b). 
Previous studies have reported the initiation of apoptosis and necrosis after ROS mediated 
cellular oxidation (Agostinis et al., 2004; Coupienne et al., 2011; Quirk et al., 2015; Schreiber et 
al., 2002). It has also been reported that several cellular signaling pathways directly regulate the 
sensitivity of the cancer cells to ALA-PDT. Previously in Dr. Hirasawa Lab, we showed that the 
Ras/MEK signaling pathway regulates the accumulation of ALA-induced PpIX in cancer cells 
(Yoshioka et al., 2018). In this study, I evaluated whether the Ras/MEK signaling pathway also 
regulates ALA-PDT sensitivity in cancer cells. 
In a cell, 5-aminolevulinic acid (5-ALA) can be metabolized into the fluorescent PS, 
protoporphyrin IX (PpIX). PpIX is further converted to heme by the enzyme ferrochelatase 
(FECH) or is effluxed out of the cells through the ABC binding cassette transporters such as 
ABCB1, ABCB6, and ABCG2 (Halani & Adamson, 2016; X. Yang et al., 2015). In cancer cells, 
exogenous treatment of 5-ALA leads to the accumulation of PpIX more efficiently than in normal 
cells due to an activated heme biosynthesis pathway and differences in the expression of 
porphyrin transporters, and mitochondrial activity (Castano et al., 2005a; Kammerer et al., 2011; 
X. Yang et al., 2015; Z. Zhang et al., 2015). Recently, our laboratory found that MEK inhibition 
increases PpIX accumulation in cancer cells. MEK, a downstream element of the Ras pathway, 




mitochondria and then out of the cell while FECH converts PpIX to heme (Kralova et al., 2017; 
Yoshioka et al., 2018). Therefore, the downregulation of ABCB1 expression and FECH activity 
results in the promotion of PpIX accumulation. Based on these findings, we were interested in 
determining whether increased PpIX accumulation in cancer cells by MEK inhibition can 
enhance 5-ALA-PDT efficacy as sufficient PpIX accumulation is essential for effective 5-ALA-
PDT. 
Based on these results, I sought to determine (objective 1) the sensitivity of different human 
cancer cell lines to 5-ALA-PDT and (objective 2) whether MEK inhibition increases 5-ALA-
PDT efficacy in vitro and in vivo. 
 
5.2. In vitro PDT and related mechanisms 
To determine the sensitivity of cancer cells (objective 1), seven human cancer cell lines (U-118, 
U-251, DLD-1, Hs 578T, H1299, MDA-MB-231, and H460) were tested. Interestingly, we found 
that the cell lines showed different sensitivities to 5-ALA-PDT (Fig 5). Based on their sensitivity 
to 5-ALA-PDT, the cell lines were classified into three groups, sensitive, moderately sensitive, 
and least sensitive. Until now, the reason behind different sensitivities to 5-ALA-PDT of all these 
cell lines has not been clarified completely. A group of researchers found that inhibition of 
expressions of ABC transporters can lead to higher PpIX accumulation and enhance PDT effects 
in glioma cell lines (Zhao et al., 2013). Studies have shown that Caspase-dependent pathways 
(Chen et al., 2002), NF-κB transcription factors (Piette et al., 2003) (Matroule et al., 2001), 
MAPK signaling pathways (Assefa et al., 1999; Klotz et al., 1998), and membrane-mediated 




regulating PDT sensitivity. Particularly related to my research project, Liu J. et al. found that 
ALA-PDT activated MEK-ERK1/2 phosphorylation, and inhibition of this pathway increased the 
anti-cancer effects of ALA-PDT (Ge et al., 2016). 
My results showed that different human cancer cell lines showed different sensitivities to 5-ALA-
PDT in vitro. The glioma cell lines (U118 and U251) were very sensitive to 5-ALA-PDT as 5-
ALA-PDT was effective even at the lowest concentration (0.2 mM) I tested, whereas the human 
lung cancer cell line (H460) was not sensitive to any concentrations of 5-ALA-PDT (0.2, 1 or 5 
mM). DLD-1, HS 578T, MDA-MB-231, and H1299 were sensitive to 5-ALA-PDT at higher 
concentrations (1 mM and 5 mM) of 5-ALA, but not at the lowest concentration (0.2 mM). There 
have been very few publications demonstrating different sensitivity of human cancer cell lines to 
5-ALA-PDT (Briel-Pump et al., 2018; Hadizadeh, 2014). As MEK inhibition restored cellular 
sensitivities to 5-ALA-PDT in the moderately and least sensitive cell lines (Fig 7), I believe that 
MEK activation modulates the cellular sensitivities. Nevertheless, the restoration of the 
sensitivities by MEK inhibition in the moderately and least sensitive cell lines was partial, 
suggesting that other cellular mechanisms are also involved in regulating cellular sensitivity to 5-
ALA-PDT. These cellular mechanisms remain to be identified in the future. It is also of interest 
to determine whether activation levels of the Ras/MEK pathway in human cancer cell lines 
correlates with their sensitivities to 5-ALA-PDT. To test this, I would conduct western blotting 
analysis against phosphorylated ERKs, which are the downstream elements of MEK, on cell 
lysate obtained from the human cancer cell lines I used in this study. Moreover, I believe it is 
important to identify further downstream elements of the Ras/MEK/ERK pathway, which 
decreases cellular sensitivity to 5-ALA-PDT. The downstream elements currently identified are 




Mitogen, and stress-activated protein kinase (MSK1-2), and ribosomal s6 kinase 1-4 (RSK1-
4)(Whitmarsh, 2006). We would need to conduct experiments using chemical inhibitors, RNAi, 
and CRISPR knockdown of the targets to identify new downstream elements. 
Several studies have explored the role of ABC transporters and the rate of PpIX efflux in 
deciding the sensitivity of the cells to ALA-PDT. It has been reported that PpIX efflux through 
ABCG2 is a key factor that regulates the sensitivity of cells to ALA-PDT (Barron et al., 2013). 
Inhibiting ABCG2 with an inhibitor, Ko-143, enhanced the efficacy of ALA-PDT in some cells. 
However, it was shown that ABCG2 inhibition could enhance PpIX accumulation even in normal 
cells leading to off-target effects of ALA-PDT (Barron et al., 2013; Yoshioka et al., 2018). Other 
studies have reported that the stage of the cell cycle and the degree of differentiation affects PDT 
sensitivity (Rollakanti et al., 2015; Wyld et al., 1998). It was shown that cells in the G1 phase 
showed lower PpIX accumulation than those in the S or G2 phases (Wyld et al., 1998). 
Furthermore, treatment with a differentiation-inducing agent such as Vitamin D enhanced ALA-
PDT efficacy (S. Anand et al., 2013; Sanjay Anand et al., 2012; Rollakanti et al., 2015). This 
suggests that the differential sensitivity of the cell lines observed in the current study may be 
attributed to different factors. It is possible that the sensitive cell lines have a higher rate of PpIX 
metabolism, which promotes PpIX accumulation at a faster rate compared to the moderately 
sensitive cells and the least sensitive cells. Conversely, the least sensitive cell line might have a 
lower accumulation of PpIX. Further studies are required to identify the underlying mechanisms 
that regulate ALA-PDT sensitivity in different cell lines. 
A previous study had reported that Ras-transformed breast cancer cells showed an increased 
accumulation of PpIX but had a lower sensitivity to ALA-PDT (Rodriguez et al., 2007). 




accumulation in the sensitive and moderately sensitive cell lines (Fig. 7), suggesting that the 
activation of the Ras/MEK pathway reduced PpIX accumulation in cancer cells. It is possible that 
other Ras downstream elements might increase PpIX accumulation, while the Ras/MEK pathway 
has the opposite effect. However, further studies are required to clarify the role of the Ras 
signaling cascade in regulating PpIX accumulation. 
To determine whether oncogenic Ras/MEK underlies cancer cell sensitivity to 5-ALA-PDT. To 
answer this question, DLD-1 and Hs 578T, which were classified as moderately sensitive cell 
lines, were chosen. Confirming the results from our previous study (Yoshioka et al., 2018), I 
found that MEK inhibition with U0126 increased PpIX accumulation in DLD-1 after 1 mM 5-
ALA treatment and in Hs 578T after 1 mM and 5 mM 5-ALA treatments by almost 3 folds (Fig 
6). 
To test objective 2, I first determined whether MEK inhibition could increase the sensitivity to 5-
ALA-PDT in the moderately sensitive cell lines. I found that combined 5-ALA-PDT with U0126 
significantly decreased cell viability in DLD-1 and Hs 578T cells compared to 5-ALA-PDT only. 
To extend my study, I also determined whether MEK inhibition restores the 5-ALA-PDT 
sensitivity of the least sensitive cell line H460. As no visible changes in the sensitivity were 
observed in H460 cells after 5-ALA-PDT at 5-ALA concentrations of 0.2, 1, and 5 mM, I 
increased the 5-ALA concentrations up to 10 mM and found that H460 cells showed a significant 
decrease in cell viability after PDT. These results demonstrate that MEK activation underlies 5-
ALA-PDT sensitivity in cancer cells. However, it should be noted that there may be other cellular 
mechanisms involved, as MEK inhibition did not completely restore 5-ALA-PDT sensitivity in 





5.3. In vivo PDT 
Next, we determined whether MEK inhibition increases 5-ALA-PDT efficacy in vivo using a 
human colon cancer xenograft model. We observed slower tumor growth, a significant decrease 
in the tumor size, and higher survival rates in combined 5-ALA-PDT with Selumetinib compared 
to treatment with vehicle control, selumetinib only, or 5-ALA-PDT only. Particularly, 4 out of 9 
mice in the combined treatment group survived until the end of the experiment (60 days), and 3 
of them were tumor-free. Our in vivo results are in line with the in vitro data and support the 
hypothesis that the Ras/MEK signaling pathway regulates the sensitivity of cancers to 5-ALA-
PDT. 
To conclude, MEK inhibitors are excellent partners of 5-ALA-PDT to promote its efficacy in 
vivo. These results need to be further confirmed using different animal models of cancer and 
preclinical trials in the future. It should be noted that one mouse in the selumetinib only group 
developed unrelated rashes and was sacrificed early. It is currently unknown how the rashes were 
caused. However, other than the rashes, I did not observe any other side effects caused by 
selumetinib or 5-ALA-PDT. 
Overall, my study demonstrates that oncogenic Ras/MEK activation underlies cancer cell 
sensitivities to 5-ALA-PDT and that MEK inhibition promotes the efficacy of 5-ALA-PDT in 
vitro and in vivo. 
 
5.4. MEK inhibitors 
The Ras/MEK pathway regulates many cellular activities, including cell proliferation, 




involved in cancer development, it has been considered as a therapeutic target. MEK inhibitors 
are widely studied and evaluated as a monotherapy or combination therapy for other cancer 
treatments. There are three MEK inhibitors (trametinib, cobimetinib, and binimetinib) that are 
approved by FDA and EMA until now (Cheng et al., 2017; Research, 2018). Patients treated with 
MEK inhibitors sometimes develop mild side effects such as rashes, peripheral edema, diarrhea, 
and fatigue (Welsh & Corrie, 2015). MEK inhibitor U0126, which is used in this study, is 
developed for in vitro and in vivo animal studies. Selumetinib is highly competitive for MEK1/2 
and is currently evaluated at Phase I and II clinical trials in humans. As the safety and efficacy of 
MEK inhibitors have been tested in clinical trials and other cancer therapeutic approaches, I 
believe that our results have a direct and immediate impact on improving 5-ALA-PDT efficacy in 
clinical settings. To further support moving our research toward clinical studies, it may be 
essential to confirm our results using the MEK inhibitors (trametinib, cobimetinib, and 
binimetinib) that have been approved by the FDA. It is also necessary to confirm the efficacy of 
combined 5-ALA-PDT with a MEK inhibitor in other animal models of cancer such as different 




Chapter 6. Conclusion and Future Directions 
6.1. Conclusion 
Various human cancer cells exhibit different sensitivity to 5-ALA-PDT. Oncogenic activation of 
the Ras/MEK pathway decreases cancer cell sensitivity to 5-ALA-PDT. MEK inhibition 
increased the 5-ALA-PDT sensitivities in vitro and in vivo. 
 
6.2. Identification of other mechanisms regulating the sensitivity to 5-ALA-PDT in various 
cancer cell lines 
We demonstrated that all seven cancer cell lines that were tested have different sensitivities to 5-
ALA-PDT. As MEK inhibition restores the cellular sensitivity to 5-ALA-PDT of moderately and 
least sensitive cell lines, I concluded that Ras/MEK activation decreases the 5-ALA-PDT 
sensitivity. As MEK inhibition, however, did not induce complete restoration, I believe that there 
are other cellular mechanisms, such as regulation by Ras downstream pathways other than MEK, 
that regulate 5-ALA-PDT sensitivity. This needs to be addressed in future studies. 
 
6.3. Determine whether other MEK inhibitors have similar effects on 5-ALA-PDT 
MEK inhibitors U0126 and Selumetinib increased 5-ALA-PDT efficacy in vitro and in vivo, 
respectively. To confirm these results, we need to use different MEK inhibitors, particularly the 
ones approved by the FDA, such as trametinib, cobimetinib, and binimetinib, and determine 





6.4. Determine whether combined 5-ALA-PDT with a MEK inhibitor is effective in 
different animal models of cancer. 
The efficacy of the combined therapy was well documented in a human colon cancer xenograft 
model in this study. Nevertheless, it remains to be determined whether the combined therapy is 
effective in other animal models of cancer, such as human cancer xenograft with other type 
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